SwissVisio
Sali, Senegal
NCT Number: NCT07480603
A new self-adjustable glaucoma drainage device has been developed. And to test its efficacy and its safety, a pilot study is designed.
This study is active but is not currently recruiting participants.
18 year–90 year
All sexes
Interventional
Phase 1
Sali, Senegal
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of primary open-angle glaucoma meeting the following criteria:
Patients must be able to understand the study requirements and provide written informed consent.
Patients must be willing to follow study instructions, agree to comply with all study procedures, and be able to attend all scheduled follow-up visits for at least 6 months after surgery.
Exclusion criteria
Pregnant or breastfeeding women, or women of childbearing potential who are not willing to use a medically acceptable method of contraception from the screening visit until the 12-month follow-up visit.
Known or suspected allergy or hypersensitivity to any component of the device (e.g., silicone).
Current participation, or participation within the last 30 days (from the screening visit), in another investigational drug or interventional device clinical trial.
Implantation of a self adjustable glaucoma drainage device
Time frame: 3 months
Type and rate of complications post-surgery
Time frame: Baseline versus every visit, up to 1 year
IOP reduction by >20%
Rheon Medical SA
Industry
Pilot Study eyeValve
Acronym: eV-SEN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07643077
Eye Diseases, Glaucoma
Ioannina, Epirus, Greece
View Trial DetailsNCT05626491
Eye Diseases, Glaucoma
Palo Alto, California, United States
View Trial DetailsNCT06666751
Eye Diseases, Glaucoma
Murray, Utah, United States
View Trial DetailsNCT06176170
Eye Diseases, Glaucoma
Sydney, New South Wales, Australia
View Trial Details